Serum uric acid and multiple sclerosis
Serum uric acid and multiple sclerosis
复制标题
DOI：
10.1016/j.clineuro.2005.08.004
复制
发表时间：
2006-09-01
影响因子：
1.9
通讯作者：
Vassilopoulos, D.
中科院分区：
文献类型：
--
作者：
Rentzos, M.;Nikolaou, C.;Vassilopoulos, D.
过氧亚硝酸盐（PN）与多发性硬化（MS）及其实验性变态反应性脑脊髓炎动物模型有关。MS患者血清尿酸（UA）水平是PN的天然清除剂，在最近的一些研究中发现其水平降低。目的：本研究的目的是将血清UA水平与MS的几个临床参数相关联。我们还试图调查过去6个月内免疫调节或免疫抑制药物治疗期间血清UA的变化。我们测量了190例MS患者和58例年龄和性别匹配的炎症性（IND）和非炎症性疾病（NIND）患者的血清UA水平作为对照组。UA水平与疾病类型、病程、残疾、磁共振成像（MRI）活动和女性gender.Results等临床参数相关：在总体MS组中，发现患者的平均血清尿酸水平显著低于IND组（p = 0.0029）和NIND组（p < 0.0001）。UA血清浓度与疾病持续时间（P = 0.87）、扩展残疾状态量表（EDSS）评分（p = 0.67）和MRI活动（p = 0.36）评估的残疾无负相关。免疫调节或免疫抑制药物治疗对UA水平无影响（p = 0.85）。临床孤立性Syndrome（CIS）患者的UA浓度显著低于IND和NIND患者（分别为p = 0.009和< 0.001）。我们的研究结果表明，MS患者血清UA水平较低可能是原发性的，对一氧化氮的保护的组成性丧失以及CNS炎症和组织损伤的发展可能对UA血清水平没有直接影响。他们还提供了支持，早期增加尿酸血清水平可能是有益的，在未来的治疗MS。（c）2005年爱思唯尔B.V.保留所有权利。
Peroxynitrite (PN) has been implicated in multiple sclerosis (MS) and its animal model experimental allergic encephalomyelitis. Uric acid (UA) serum levels of MS patients, a natural scavenger of PN, were found lowered in some recent studies.Objective/purpose: The objective of our study was to correlate UA serum levels and several clinical parameters of MS. We also tried to investigate serum UA changes during treatment with immunomodulating or immunosuppressing drugs in the last 6 months.Patients and methods: We measured UA serum levels in 190 patients with MS and 58 age and gender matched patients with inflammatory (IND) and non-inflammatory diseases (NIND) studied as control groups. UA levels were correlated with clinical parameters as type of the disease, duration, disability, magnetic resonance imaging (MRI) activity and female gender.Results: In the overall MS group, patients were found to have significantly lower mean serum uric acid levels compared with the IND (p = 0.0029) and the NIND group (p < 0.0001). UA serum concentrations were not inversely correlated with duration of the disease (P = 0.87), with disability as assessed by Expanded Disability Status Scale (EDSS) score (p = 0.67) and MRI activity (p = 0.36). Treatment with immunomodulating or immunosuppressing drugs had no influence in UA levels (p = 0.85). Patients with Clinically Isolated Syndromes (CIS) were found to have significantly lower UA concentrations compared with IND and NIND patients (p = 0.009 and < 0.001, respectively).Conclusions: Our findings suggest that lower serum UA levels in MS patients may represent a primary, constitutive loss of protection against nitric oxide and the development of CNS inflammation and tissue damage may not have a direct effect to UA serum levels. They also provide support that the earlier increase of UA serum levels might be beneficial in the future treatment of MS. (c) 2005 Elsevier B.V. All rights reserved.